FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283380286> ?p ?o ?g. }

• W4283380286 endingPage "e004984" @default.
• W4283380286 startingPage "e004984" @default.
• W4283380286 abstract "Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin’s lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade targeting program death receptor 1 would be effective in PTCL, we conducted an investigator-initiated phase 2 prospective study of single-agent nivolumab for RR PTCL. We report here results of the pre-specified interim analysis. Methods The primary objective was to assess the overall response rate (ORR). Secondary objectives were to assess safety and tolerability of nivolumab in PTCL and to assess progression-free survival (PFS), duration of response (DOR) and overall survival (OS). Hyperprogressive disease (HPD) was defined as time-to-treatment failure of less than or equal to one month from initiation of therapy. Results Twelve patients who received at least one cycle of nivolumab were included in this interim analysis. Half (6/12) of the patients had angioimmunoblastic T-cell lymphoma (AITL), 3/12 had PTCL, not otherwise specified. Most (11/12) were advanced stage, had extranodal disease (97.1%) and had received a prior autologous stem cell transplant (50%). The ORR was 33% (95% CI: 12.3 to 63.7%) with two complete response and two partial response. The median PFS was however short at 2.7 months (95% CI: 1.5 to NE); and the median OS was 6.7 months (95% CI: 3.4 to NE). The median DOR was also short at 3.6 months (95% CI: 1.9 to NE). HPD occurred in four patients, three of whom had AITL. Observed grade 3 and higher adverse events (AEs) were non-hematologic in 5/12 (42%), while hematologic AEs were seen in 3/12 (25%). Conclusions Nivolumab had modest clinical activity in R/R PTCL. Due to a high number of hyperprogression and short DOR, a decision was made to halt the study. These findings likely reflect the distinct biology of PTCL and should be considered when designing future studies using checkpoint inhibitors in these diseases. Trial registration number NCT03075553 ." @default.
• W4283380286 created "2022-06-25" @default.
• W4283380286 creator A5004152557 @default.
• W4283380286 creator A5027785733 @default.
• W4283380286 creator A5040160436 @default.
• W4283380286 creator A5048644166 @default.
• W4283380286 creator A5052702492 @default.
• W4283380286 creator A5059729547 @default.
• W4283380286 creator A5061713890 @default.
• W4283380286 creator A5069952110 @default.
• W4283380286 creator A5080184636 @default.
• W4283380286 creator A5090406453 @default.
• W4283380286 date "2022-06-01" @default.
• W4283380286 modified "2023-10-05" @default.
• W4283380286 title "Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression" @default.
• W4283380286 cites W1966621240 @default.
• W4283380286 cites W1980040544 @default.
• W4283380286 cites W1985563120 @default.
• W4283380286 cites W2000589976 @default.
• W4283380286 cites W2014016342 @default.
• W4283380286 cites W2028352405 @default.
• W4283380286 cites W2033866193 @default.
• W4283380286 cites W2051838890 @default.
• W4283380286 cites W2065631872 @default.
• W4283380286 cites W2070705354 @default.
• W4283380286 cites W2109716912 @default.
• W4283380286 cites W2116068882 @default.
• W4283380286 cites W2116823767 @default.
• W4283380286 cites W2125616358 @default.
• W4283380286 cites W2133201432 @default.
• W4283380286 cites W2146112074 @default.
• W4283380286 cites W2170069789 @default.
• W4283380286 cites W2216639295 @default.
• W4283380286 cites W2310716991 @default.
• W4283380286 cites W2416844197 @default.
• W4283380286 cites W2544675721 @default.
• W4283380286 cites W2554618897 @default.
• W4283380286 cites W2573926257 @default.
• W4283380286 cites W2601621622 @default.
• W4283380286 cites W2603029028 @default.
• W4283380286 cites W2762417951 @default.
• W4283380286 cites W2769936894 @default.
• W4283380286 cites W2792211393 @default.
• W4283380286 cites W2804364560 @default.
• W4283380286 cites W2883753290 @default.
• W4283380286 cites W2901379105 @default.
• W4283380286 cites W2906944961 @default.
• W4283380286 cites W2928054908 @default.
• W4283380286 cites W2938362298 @default.
• W4283380286 cites W2941582519 @default.
• W4283380286 cites W2970310602 @default.
• W4283380286 cites W2991361825 @default.
• W4283380286 cites W2993726184 @default.
• W4283380286 cites W3033353648 @default.
• W4283380286 cites W3097595278 @default.
• W4283380286 cites W3103602933 @default.
• W4283380286 cites W3175852418 @default.
• W4283380286 doi "https://doi.org/10.1136/jitc-2022-004984" @default.
• W4283380286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35750419" @default.
• W4283380286 hasPublicationYear "2022" @default.
• W4283380286 type Work @default.
• W4283380286 citedByCount "20" @default.
• W4283380286 countsByYear W42833802862021 @default.
• W4283380286 countsByYear W42833802862022 @default.
• W4283380286 countsByYear W42833802862023 @default.
• W4283380286 crossrefType "journal-article" @default.
• W4283380286 hasAuthorship W4283380286A5004152557 @default.
• W4283380286 hasAuthorship W4283380286A5027785733 @default.
• W4283380286 hasAuthorship W4283380286A5040160436 @default.
• W4283380286 hasAuthorship W4283380286A5048644166 @default.
• W4283380286 hasAuthorship W4283380286A5052702492 @default.
• W4283380286 hasAuthorship W4283380286A5059729547 @default.
• W4283380286 hasAuthorship W4283380286A5061713890 @default.
• W4283380286 hasAuthorship W4283380286A5069952110 @default.
• W4283380286 hasAuthorship W4283380286A5080184636 @default.
• W4283380286 hasAuthorship W4283380286A5090406453 @default.
• W4283380286 hasBestOaLocation W42833802861 @default.
• W4283380286 hasConcept C121332964 @default.
• W4283380286 hasConcept C121608353 @default.
• W4283380286 hasConcept C126322002 @default.
• W4283380286 hasConcept C142424586 @default.
• W4283380286 hasConcept C143998085 @default.
• W4283380286 hasConcept C197934379 @default.
• W4283380286 hasConcept C203014093 @default.
• W4283380286 hasConcept C2776090121 @default.
• W4283380286 hasConcept C2776694085 @default.
• W4283380286 hasConcept C2777701055 @default.
• W4283380286 hasConcept C2777891184 @default.
• W4283380286 hasConcept C2778375690 @default.
• W4283380286 hasConcept C2778822529 @default.
• W4283380286 hasConcept C2779134260 @default.
• W4283380286 hasConcept C2779338263 @default.
• W4283380286 hasConcept C2780030458 @default.
• W4283380286 hasConcept C2780739268 @default.
• W4283380286 hasConcept C535046627 @default.
• W4283380286 hasConcept C61943457 @default.
• W4283380286 hasConcept C71924100 @default.
• W4283380286 hasConcept C87355193 @default.

• next